AU Patent

AU2019354391A1 — Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors

Assigned to Adicet Therapeutics Inc · Expires 2021-05-06 · 5y expired

What this patent protects

Aspects of the invention include compositions and methods for treatment of hematological tumors with engineered or non-engineered γδ-T cells. In some embodiments, the γδ-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-CD20 bindi…

USPTO Abstract

Aspects of the invention include compositions and methods for treatment of hematological tumors with engineered or non-engineered γδ-T cells. In some embodiments, the γδ-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-CD20 binding domain or anti-B cell maturation antigen (BCMA) binding domain, a CD8 hinge and transmembrane domain, a costimulatory domain, a CD3 ζ signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as a sIL15 domain.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019354391A1
Jurisdiction
AU
Classification
—
Expires
2021-05-06
Drug substance claim
No
Drug product claim
No
Assignee
Adicet Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.